trending Market Intelligence /marketintelligence/en/news-insights/trending/atyhtk3VwWwIahNuPfMZvg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Allergan Q2 income, revenue up YOY; raises FY'17 guidance

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Allergan Q2 income, revenue up YOY; raises FY'17 guidance

Allergan plc reported $1.44 billion, or $4.02 per share, in second quarter non-GAAP earnings, an increase from $1.40 billion, or $3.35 per share, in the same quarter of 2016.

The S&P Capital IQ normalized EPS consensus estimate for the second quarter was $3.92.

Allergan generated $4.01 billion in second-quarter revenues, an increase of 8.8% year over year. "Revenue growth in the second quarter was powered by significant year-over-year gains from many of our top products, solid contribution from our launch products and successful integrations of LifeCell and ZELTIQ," Allergan Chairman and CEO Brent Saunders said in a statement.

The company reported second quarter non-GAAP adjusted EBITDA of $2.03 billion, an increase of 4.8% year over year. The company's second quarter adjusted operating income was up 1.6% year over year to $1.89 billion.

Allergan's second-quarter GAAP loss widened year over year to $717.5 million, or $2.14 per share, from $424.4 million, or $1.07 per share, in the same quarter of 2016.

The company's second quarter operating loss also widened to $902.4 million from $487.6 million in the second quarter of 2016.

Allergan raised its full-year non-GAAP EPS guidance to a range of $16.05 to $16.45 from $15.85 to $16.35 previously.

The S&P Capital IQ normalized EPS consensus estimate for 2017 is $16.08.

Full-year 2017 GAAP loss per share is now expected to be in the range of $10.80 to $11.20 as opposed to $9.70 to $10.20 previously.

The company raised its full-year revenues guidance to a range of $15.85 billion to $16.05 billion from $15.80 billion to $16 billion previously.